Servier Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Suresnes France (1954)

Organization Overview

First Clinical Trial
2000
NCT00122811
First Marketed Drug
1994
pegaspargase (oncaspar)
First NDA Approval
2018
calaspargase pegol (Asparlas)
Last Known Activity
2025

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ADIR, a Servier Group company | Biogaran | Institut de Recherches Internationales Servier | Institut de Recherches Internationales Servier (I.R.I.S.) | Les Laboratoires Servier (LLS) | Les Laboratoires Servier (L.L.S), Russia | Servier | SERVIER | Servier Affaires Médicales | Servier Bio-Innovation LLC | Servier Laboratories (Australia) Pty Ltd | Servier Pharmaceuticals LLC | Servier Pharmaceuticals, LLC | SERVIER PHARMA LLC

Active Ingredients

Marketed Drugs (4)

Key: Servier (2) Acquired (2)

calaspargase pegol (Asparlas) (2018 NDA)

ivosidenib (tibsovo) (2018)

mitapivat (Pyrukynd) (2022 NDA)

pegaspargase (oncaspar) (1994)

Drugs in Phase 4 Trials (12)

Key: Servier (11) Acquired (1)

agomelatine (Valdoxan) (4 trials)

amlodipine (norvasc) (3 trials)

atorvastatin (lipitor) (2 trials)

diosmetine (2 trials)

escitalopram (lexapro) (1 trial)

gliclazide (3 trials)

Hesperedin (1 trial)

indapamide (lozol) (3 trials)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (1 trial)

mitapivat (Pyrukynd) (21 trials)

perindopril (aceon) (10 trials)

Drugs in Phase 3 Trials (26)

Key: Servier (19) Acquired (7)

azacitidine (vidaza) (6 trials)

bevacizumab (avastin) (4 trials)

bisoprolol (zebeta) (1 trial)

bumetanide (bumex) (2 trials)

calaspargase pegol (Asparlas) (4 trials)

capecitabine (xeloda) (6 trials)

captopril (capoten) (1 trial)

dexamethasone (2 trials)

doxorubicin (Doxil) (2 trials)

enalapril (vasotec) (1 trial)

fotemustine (1 trial)

futuximab (11 trials)

gevokizumab (4 trials)

imatinib (gleevec) (1 trial)

inotuzumab ozogamicin (besponsa) (1 trial)

ivabradine (corlanor) (7 trials)

ivosidenib (tibsovo) (23 trials)

lamotrigine (lamictal) (3 trials)

lisinopril (zestril) (1 trial)

modotuximab (4 trials)

omecamtiv mecarbil (2 trials)

ramipril (altace) (2 trials)

tipiracil (lonsurf) (13 trials)

trandolapril (mavik) (1 trial)

trifluridine (viroptic) (13 trials)

vincristine (oncovin) (2 trials)

Drugs in Phase 2 Trials (33)

Key: Servier (21) Acquired (12)

ag-946 (2 trials)

carboplatin (paraplatin) (1 trial)

cemiplimab (libtayo) (1 trial)

docetaxel (taxotere) (2 trials)

enasidenib (idhifa) (4 trials)

fluorouracil (efudex) (7 trials)

glpg1972 (1 trial)

gnbac1 (2 trials)

ipilimumab (yervoy) (1 trial)

irinotecan (Camptosar) (6 trials)

leucovorin (7 trials)

lucitanib (2 trials)

mik665 (2 trials)

nivolumab (opdivo) (4 trials)

ose-127 (2 trials)

oxaliplatin (eloxatin) (6 trials)

paclitaxel (taxol) (3 trials)

pegaspargase (oncaspar) (3 trials)

pembrolizumab (keytruda) (2 trials)

prs-344 (1 trial)

s095018 (1 trial)

s095024 (1 trial)

s095029 (3 trials)

s095033 (1 trial)

s18986 (1 trial)

s 44819 (1 trial)

s47445 (2 trials)

s65487 (2 trials)

s81694 (1 trial)

sym013 (1 trial)

sym015 (1 trial)

symphoglobulin-d (1 trial)

venetoclax (venclexta) (2 trials)

Drugs in Phase 1 Trials (34)

Key: Servier (15) Acquired (19)

ag-270 (1 trial)

ag-519 (1 trial)

ag-636 (1 trial)

cd19 car-t cells (3 trials)

ciprofloxacin (cipro) (1 trial)

cobimetinib (cotellic) (1 trial)

cytarabine (cytosar-u) (3 trials)

daunorubicin (cerubidine) (1 trial)

dexrazoxane (zinecard) (1 trial)

etoposide (vepesid) (1 trial)

Filgrastim (neupogen) (1 trial)

Flotetuzumab (1 trial)

fludarabine (fludara) (1 trial)

gemcitabine (gemzar) (1 trial)

hydrocortisone (solu-cortef) (1 trial)

idarubicin (idamycin) (1 trial)

itraconazole (sporanox) (2 trials)

methotrexate (1 trial)

mitoxantrone (novantrone) (1 trial)

mrg-110 (1 trial)

omeprazole (prilosec) (1 trial)

pepidh1m (1 trial)

prednisolone (hydeltra) (1 trial)

rifampin (1 trial)

rituximab (rituxan) (1 trial)

s095012 (1 trial)

s 55746 (2 trials)

s64315 (1 trial)

s95029 (1 trial)

sym021 (4 trials)

sym022 (3 trials)

sym023 (3 trials)

sym024 (1 trial)

Vorasidenib (11 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Angina Pectoris (Phase 3)

Angina, Stable (Phase 3)

Atrial Fibrillation (Phase 3)

Autism Spectrum Disorder (Phase 3)

Autistic Disorder (Phase 3)

Behcet Syndrome (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Cardiovascular Diseases (Phase 1)

Child Development Disorders, Pervasive (Phase 3)

Cholangiocarcinoma (Phase 2)

Cognitive Dysfunction (Phase 2)

Colorectal Neoplasms (Phase 3)

Compulsive Personality Disorder (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Disease (Phase 4)

Essential Hypertension (Phase 4)

Heart Failure (Phase 3)

Hypercholesterolemia (Phase 4)

Hypertension (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Diseases (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 3)

Multiple Myeloma (Phase 1)

Multiple Organ Failure (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Myocardial Ischemia (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 1)

Obsessive-Compulsive Disorder (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 1)

Proctitis (Phase 3)

Psychotic Disorders (Phase 4)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 3)

Schizophrenia (Phase 4)

Schizophrenia, Paranoid (Phase 4)

Sclerosis (Phase 2)

Sjogren's Syndrome (Phase 2)

Syndrome (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Uveal Neoplasms (Phase 3)

Uveitis (Phase 3)

Vascular Diseases (Phase 3)

Venous Insufficiency (Phase 4)

Ventricular Dysfunction (Phase 3)

Ventricular Dysfunction, Left (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 170
  • # of Trial APIs: 105